[18F]Fluorodeoxyglucose positron emission tomography-computerized tomography and lung cancer: A significant referral bias exists

European Journal of Cardio-thoracic Surgery

Volumn 39, Issue 4, 2011, Pages 560-564

  Okereke, Ikenna C ^a   Gangadharan, Sidhu P ^b   Kent, Michael S ^b   Nicotera, Saila P ^b   DeCamp, Malcolm M ^b  

^a INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Diagnostic accuracy; Lung cancer; Oncology

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GOLD STANDARD; HUMAN; LUNG BIOPSY; LUNG CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; MEDIASTINOSCOPY; MEDIASTINUM; PERCUTANEOUS BIOPSY; PRIORITY JOURNAL; QUALITATIVE RESEARCH; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; THORACOCENTESIS; EPIDEMIOLOGY; EVALUATION; LUNG TUMOR; MIDDLE AGED; MORTALITY; PATIENT REFERRAL; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; SCINTISCANNING; STATISTICS; SURVIVAL;

AGED; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; REFERRAL AND CONSULTATION; SELECTION BIAS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS;

EID: 79952537022     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcts.2010.07.039     Document Type: Article

References (15)

1. Antoch G., Stattaus J., Nemat A., Marnitz S., Beyer T., Keuhl H., Bockisch A., Debatin J., Freudenberg L. Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. Radiology 2003, 229:526-533.
2. Punglia R., D'Amico A., Catalona W., Roehl K., Kuntz K. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med 2003, 349:335-342.
3. Roger V., Pellikka P., Bell M., Chow C., Bailey K., Seward J. Sex and test verification bias. Impact on the diagnostic value of exercise echocardiography. Circulation 1997, 95(2):405-410.
4. Lauer M., Murthy S., Blackstone E., Okereke I., Rice T. [18F]Fluorodeoxyglucose uptake by positron emission tomography for diagnosis of suspected lung cancer: impact of verification bias. Arch Intern Med 2007, 167(2):161-165.
5. Diamond G. Affirmative actions: can the discriminant accuracy of a test be determined in the face of selection bias?. Med Decis Making 1991, 11:48-56.
6. Diamond G. Reverend Bayes' silent majority: an alternative factor affecting sensitivity and specificity of exercise electrocardiography. Am J Cardiol 1986, 57:1175-1180.
7. Begg C., Greenes R. Assessment of diagnostic tests when disease verification is subject to bias. Biometrics 1983, 39:207-215.
8. Mountain C. Revisions in the international system for staging lung cancer. Chest 1997, 111:1710-1717.
9. Patz E., Lowe V., Hoffman J., Paine S., Burrowes P., Coleman R., Goodman P. Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology 1993, 188:487-490.
10. Bloemenkamp K., Rosendaal F., Buller H., Helmerhorst F., Colly L., Vandenbroucke J. Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias. Arch Intern Med 1999, 159:65-70.
11. Tournoy K., Maddens S., Gosselin R., Van Maele G., Van Meerbeeck J., Kelles A. Integrated FDG-PET/CT does not make invasive staging of the intrathoracic lymph nodes in non-small cell lung cancer redundant: a prospective study. Thorax 2007, 62(8):696-701.
12. Cheran S., Nielsen N., Patz E. False-negative findings for primary lung tumors on FDG positron emission tomography: staging and prognostic implications. AJR 2004, 182:1129-1132.
13. Sasaki R., Komaki R., Macapinlac H., Erasmus J., Allen P., Forster K., Putnam J., Herbst R., Moran C., Podoloff D., Roth J., Cox J. [18F]Fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol 2005, 23(6):1136-1143.
14. Ahuja V., Coleman R., Herndon J., Patz E. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with non-small cell lung carcinoma. Cancer 1998, 83(5):918-924.
15. Line B., Maragh M., Ahamed T. Positron emission tomography imaging of lung and esophageal cancer. Appl Radiol 2002, 31(6):9-17.